Free tool
FAERS Monitor: Gemcitabine Hydrochloride
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209604 or its brand name (Gemcitabine Hydrochloride, Gemcitabine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
14,000
Serious
13,603
97% of reports
Hospitalization
6,282
Death reported
2,613
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,385
- myelosuppression1,153
- malignant neoplasm progression846
- thrombocytopenia766
- anaemia679
- neutropenia668
- pyrexia667
- nausea627
- vomiting534
- platelet count decreased505
- diarrhoea498
- death490
- neoplasm progression478
- febrile neutropenia463
- fatigue449
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 14 |
| 2005 | 14 |
| 2006 | 31 |
| 2007 | 1 |
| 2008 | 4 |
| 2009 | 5 |
| 2010 | 89 |
| 2011 | 486 |
| 2012 | 629 |
| 2013 | 482 |
| 2014 | 489 |
| 2015 | 457 |
| 2016 | 534 |
| 2017 | 597 |
| 2018 | 768 |
| 2019 | 1,148 |
| 2020 | 1,112 |
| 2021 | 1,018 |
| 2022 | 1,028 |
| 2023 | 1,189 |
| 2024 | 1,542 |
| 2025 | 1,394 |
| 2026 | 969 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,159 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelosuppressionSignal | 1,153 | 49.6 | 46.9 | 53,249 |
| neoplasm progressionSignal | 478 | 20.9 | 19.2 | 8,943 |
| malignant neoplasm progressionSignal | 846 | 12.5 | 11.7 | 8,914 |
| febrile neutropeniaSignal | 463 | 10.6 | 9.6 | 3,979 |
| thrombocytopeniaSignal | 766 | 10.4 | 9.7 | 6,455 |
| neutropeniaSignal | 668 | 7.4 | 6.9 | 3,705 |
| platelet count decreasedSignal | 505 | 7.1 | 6.6 | 2,665 |
| anaemiaSignal | 679 | 5.4 | 5.0 | 2,420 |
| pyrexiaSignal | 667 | 2.9 | 2.7 | 840 |
| off label useSignal | 1,385 | 2.4 | 2.3 | 1,151 |
| vomiting | 534 | 1.7 | 1.6 | 159 |
| nausea | 627 | 1.2 | 1.1 | 20 |
| diarrhoea | 498 | 1.2 | 1.1 | 11 |
| fatigue | 449 | 0.9 | 0.8 | 9 |
| death | 490 | 0.9 | 0.8 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.